erenumab

Showing 2 posts of 2 posts found.

amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

Amgen, Novartis migraine drug meets primary endpoint in Phase II study

June 9, 2016
Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine

A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …

The Gateway to Local Adoption Series

Latest content